A 42-year-old woman with newly diagnosed drug-susceptible pulmonary tuberculosis is being started on anti-TB therapy. She has no contraindications. According to WHO and Indian TB guidelines, which drug is the preferred choice for the continuation phase (after the 2-month intensive phase) in this patient?